ProMIS Neurosciences Shares Rise on Upcoming Alzheimer's Trial Update

Dow Jones07-28

Shares of ProMIS Neurosciences rose after the company said it will host a webinar to discuss six-month, blinded interim results from an early-stage study of its Alzheimer's antibody, PMN310.

Shares were recently up about 17% at $13.69 in after-h

The clinical-stage biotechnology company said the webinar is scheduled for 8 a.m. ET on Tuesday and will cover safety findings and overall trends in selected lab markers from patients in the study.

ours trading Monday. The stock is up about 72% year to date.

The update comes from a Phase 1b trial, an early study that tests safety and dosing in a small group of people and is still blinded, meaning individual results are not revealed yet.

Write to Doc Louallen at Doc.Louallen@wsj.com

(END) Dow Jones Newswires

July 27, 2026 17:54 ET (21:54 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2654025201?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 05:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654025201","market":"us","top_or_hot":-1,"title":"ProMIS Neurosciences Shares Rise on Upcoming Alzheimer's Trial Update","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/PMN\">ProMIS Neurosciences</a> rose after the company said it will host a webinar to discuss six-month, blinded interim results from an early-stage study of its Alzheimer's antibody, PMN310. \n</p>\n<p>\n  Shares were recently up about 17% at $13.69 in after-h \n</p>\n<p>\n  The  clinical-stage biotechnology company said the webinar is scheduled for 8 a.m. ET on Tuesday and will cover safety findings and overall trends in selected lab markers from patients in the study. \n</p>\n<p>\n  ours trading Monday. The stock is up about 72% year to date. \n</p>\n<p>\n  The update comes from a Phase 1b trial, an early study that tests safety and dosing in a small group of people and is still blinded, meaning individual results are not revealed yet. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 27, 2026 17:54 ET (21:54 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ProMIS Neurosciences Shares Rise on Upcoming Alzheimer's Trial Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProMIS Neurosciences Shares Rise on Upcoming Alzheimer's Trial Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-28 05:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/PMN\">ProMIS Neurosciences</a> rose after the company said it will host a webinar to discuss six-month, blinded interim results from an early-stage study of its Alzheimer's antibody, PMN310. \n</p>\n<p>\n  Shares were recently up about 17% at $13.69 in after-h \n</p>\n<p>\n  The  clinical-stage biotechnology company said the webinar is scheduled for 8 a.m. ET on Tuesday and will cover safety findings and overall trends in selected lab markers from patients in the study. \n</p>\n<p>\n  ours trading Monday. The stock is up about 72% year to date. \n</p>\n<p>\n  The update comes from a Phase 1b trial, an early study that tests safety and dosing in a small group of people and is still blinded, meaning individual results are not revealed yet. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 27, 2026 17:54 ET (21:54 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2654025201","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654025201","pubTimestamp":1785189240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ProMIS Neurosciences rose after the company said it will host a webinar to discuss six-month, blinded interim results from an early-stage study of its Alzheimer's antibody, PMN310.Shares were recently up about 17% at $13.69 in after-hThe  clinical-stage biotechnology company said the webinar is scheduled for 8 a.m. ET on Tuesday and will cover safety findings and overall trends in selected lab markers from patients in the study.ours trading Monday. The stock is up about 72% year to date.The update comes from a Phase 1b trial, an early study that tests safety and dosing in a small group of people and is still blinded, meaning individual results are not revealed yet.Write to Doc Louallen at Doc.Louallen@wsj.com Dow Jones NewswiresJuly 27, 2026 17:54 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PMN":"ProMIS Neurosciences Inc"},"translate_title":"ProMIS Neurosciences 股价因即将发布的阿尔茨海默氏症试验更新而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PMN":0.9},"content_text":"Shares of ProMIS Neurosciences rose after the company said it will host a webinar to discuss six-month, blinded interim results from an early-stage study of its Alzheimer's antibody, PMN310. \n\n\n  Shares were recently up about 17% at $13.69 in after-h \n\n\n  The  clinical-stage biotechnology company said the webinar is scheduled for 8 a.m. ET on Tuesday and will cover safety findings and overall trends in selected lab markers from patients in the study. \n\n\n  ours trading Monday. The stock is up about 72% year to date. \n\n\n  The update comes from a Phase 1b trial, an early study that tests safety and dosing in a small group of people and is still blinded, meaning individual results are not revealed yet. \n\n\n \n\n\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 27, 2026 17:54 ET (21:54 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654025201","isCrawlerRequest":true}